Raymond Urbanski

538 total citations
12 papers, 422 citations indexed

About

Raymond Urbanski is a scholar working on Genetics, Hematology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Raymond Urbanski has authored 12 papers receiving a total of 422 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 5 papers in Hematology and 3 papers in Cellular and Molecular Neuroscience. Recurrent topics in Raymond Urbanski's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Eosinophilic Disorders and Syndromes (3 papers). Raymond Urbanski is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Eosinophilic Disorders and Syndromes (3 papers). Raymond Urbanski collaborates with scholars based in United States, Taiwan and China. Raymond Urbanski's co-authors include Hreday N. Sapru, Abbott J. Krieger, Susan Punnen, Stephen L. Carrithers, Scott A. Waldman, Scott D. Goldstein, Scott J. Parkinson, Albert Qin, John Mascarenhas and Craig Zimmerman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Brain Research.

In The Last Decade

Raymond Urbanski

11 papers receiving 410 citations

Peers

Raymond Urbanski
Junli Wang China
Michael Heiber Canada
Tianyi Zhu China
Sulekha Verma United States
Marcella Ma United Kingdom
Travis McMurphy United States
Joshua A Vieth United States
Chris Chapman United Kingdom
J.J. Maoret France
Kathryn M. Oliver Ireland
Junli Wang China
Raymond Urbanski
Citations per year, relative to Raymond Urbanski Raymond Urbanski (= 1×) peers Junli Wang

Countries citing papers authored by Raymond Urbanski

Since Specialization
Citations

This map shows the geographic impact of Raymond Urbanski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond Urbanski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond Urbanski more than expected).

Fields of papers citing papers by Raymond Urbanski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raymond Urbanski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond Urbanski. The network helps show where Raymond Urbanski may publish in the future.

Co-authorship network of co-authors of Raymond Urbanski

This figure shows the co-authorship network connecting the top 25 collaborators of Raymond Urbanski. A scholar is included among the top collaborators of Raymond Urbanski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raymond Urbanski. Raymond Urbanski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Masárová, Lucia, John Mascarenhas, Albert Qin, et al.. (2023). EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.. Journal of Clinical Oncology. 41(16_suppl). TPS7088–TPS7088.
2.
3.
Mesa, Ruben A., Norio Komatsu, Harinder Gill, et al.. (2022). MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia. Clinical Lymphoma Myeloma & Leukemia. 22. S342–S342. 4 indexed citations
4.
Verstovšek, Srđan, Ruben A. Mesa, John Mascarenhas, et al.. (2022). MPN-546 A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia. Clinical Lymphoma Myeloma & Leukemia. 22. S342–S343. 1 indexed citations
5.
Verstovšek, Srđan, Norio Komatsu, Harinder Gill, et al.. (2022). SURPASS-ET: phase III Study of Ropeginterferon Alfa-2b versus Anagrelide as Second-Line Therapy in Essential Thrombocythemia. Future Oncology. 18(27). 2999–3009. 18 indexed citations
6.
7.
Carrithers, Stephen L., et al.. (1996). Escherichia coli heat-stable enterotoxin receptors. Diseases of the Colon & Rectum. 39(2). 171–181. 56 indexed citations
8.
Urbanski, Raymond, Stephen L. Carrithers, & Scott A. Waldman. (1995). Internalization of E. coli ST mediated by guanylyl cyclase C in T84 human colon carcinoma cells. Biochimica et Biophysica Acta (BBA) - General Subjects. 1245(1). 29–36. 29 indexed citations
9.
Urbanski, Raymond, et al.. (1989). Cardiovascular effects of substance P receptor stimulation in the ventrolateral medullary pressor and depressor areas. Brain Research. 491(2). 383–389. 15 indexed citations
10.
Urbanski, Raymond & Hreday N. Sapru. (1988). Putative neurotransmitters involved in medullary cardiovascular regulation. Journal of the Autonomic Nervous System. 25(2-3). 181–193. 89 indexed citations
11.
Urbanski, Raymond & Hreday N. Sapru. (1988). Evidence for a sympathoexcitatory pathway from the nucleus tractus solitarii to the ventrolateral medullary pressor area. Journal of the Autonomic Nervous System. 23(2). 161–174. 92 indexed citations
12.
Punnen, Susan, Raymond Urbanski, Abbott J. Krieger, & Hreday N. Sapru. (1987). Ventrolateral medullary pressor area: site of hypotensive action of clonidine. Brain Research. 422(2). 336–346. 101 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Junli Wang Breakdown of academic impact, for papers by Michael Heiber Breakdown of academic impact, for papers by Tianyi Zhu Breakdown of academic impact, for papers by Sulekha Verma Breakdown of academic impact, for papers by Marcella Ma Breakdown of academic impact, for papers by Travis McMurphy Breakdown of academic impact, for papers by Joshua A Vieth Breakdown of academic impact, for papers by Chris Chapman Breakdown of academic impact, for papers by J.J. Maoret Breakdown of academic impact, for papers by Kathryn M. Oliver
Rankless by CCL
2026